Plasma Injections for Knee Osteoarthritis

(A2MRP Trial)

Overseen By Erin Hennessey

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Mayo Clinic

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA).

Research Team

Brennan Boettcher, D.O

Principal Investigator

Mayo Clinic

Eligibility Criteria

This trial is for adults aged 18-65 with moderate knee osteoarthritis, experiencing pain greater than 4 on a scale of 0-10. Participants must have tried conservative treatments for over six weeks and be fluent in English. Excluded are pregnant individuals, those with recent infections or surgeries in the target knee, BMI over 35, significant knee deformity or alignment issues, chronic immunosuppression, or current tobacco/nicotine use.

Inclusion Criteria

My worst knee pain is more than 4 out of 10.

I have moderate knee pain from arthritis without severe damage in certain knee areas.

Speak fluent English

Exclusion Criteria

Pregnant or nursing, or planning on becoming pregnant during the study period

My knee had an infection or currently has one.

I have a significant inflammatory or rheumatological condition.

Treatment Details

Interventions

• Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) (Biological)

Trial Overview The study tests the safety and effectiveness of A2MRP injections directly into the knee to treat symptoms of osteoarthritis. It aims to see if this treatment can reduce pain and improve joint function compared to standard therapies.

Participant Groups

Group I: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) Experimental Treatment 1 Intervention

Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) is produced by filtering Platelet Poor Plasma (PPP), a Platelet Rich Plasma byproduct, through a hemoconcentrator filter. (PPP) is frequently used in clinical practice to increase volume of PRP or Bone Marror Aspirate Concentrate (BMAC) injectate, and it is occasionally injected in isolation for some indication

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+